"Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said. They wouldn't describe the study in any further detail because, they said, its disclosure would be "market-moving"..."
The timing of the data release for Galidesivir Brazilian trial Part 1 does make sense this coming week. Dosing for the 24 patients in Part 1 began May 5/6 according to Dr Kallas, the Principal Investigator, in one of his Youtube videos. Come this Monday it will be 62 days.
Next, focus on the last sentence of the clinical trial's Detailed Description: "All patients will be followed for mortality through Day 56." Since this is the first Galidesivir COVID-19 human trial they at least want "complete data" from Part 1 to cover their asses, hence they wait until Day 56?
CEO Stonehouse 5/6/20 CC: "We look forward to updating you on what we see in Part 1 and how that data informs our dose selection & progress in Part 2."